BR112013008034A2 - método para normalizar hemeostase comprometida - Google Patents

método para normalizar hemeostase comprometida

Info

Publication number
BR112013008034A2
BR112013008034A2 BR112013008034A BR112013008034A BR112013008034A2 BR 112013008034 A2 BR112013008034 A2 BR 112013008034A2 BR 112013008034 A BR112013008034 A BR 112013008034A BR 112013008034 A BR112013008034 A BR 112013008034A BR 112013008034 A2 BR112013008034 A2 BR 112013008034A2
Authority
BR
Brazil
Prior art keywords
hemeostasis
compromised
normalize
coagulation factor
fii
Prior art date
Application number
BR112013008034A
Other languages
English (en)
Inventor
Ann Lövgren
Kenny Hansson
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013008034(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112013008034A2 publication Critical patent/BR112013008034A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método para normalizar hemeostase comprometida. a presente invenção se refere à normalização de hemeostase comprometida, sendo que compreende administrar um tratamento de fator de coagulação selecionado a partir do grupo que consiste em (1) fii; (2) pcc; e (30 uma combinação dous três fatores de fii, fx e fviia. o tratamento de fator de coagulação pode ser administrado em combinação com fibrinogênio. o(s) fator(es) de coagulação pode(m) ser fator(es) de coagulação recombinante(s) humano(s).
BR112013008034A 2010-10-06 2011-09-19 método para normalizar hemeostase comprometida BR112013008034A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06
PCT/EP2011/066241 WO2012045569A1 (en) 2010-10-06 2011-09-19 Factor ii and fibrinogen for treatment of haemostatic disorders

Publications (1)

Publication Number Publication Date
BR112013008034A2 true BR112013008034A2 (pt) 2016-06-14

Family

ID=44677879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008034A BR112013008034A2 (pt) 2010-10-06 2011-09-19 método para normalizar hemeostase comprometida

Country Status (16)

Country Link
US (1) US9433664B2 (pt)
EP (1) EP2624859B1 (pt)
JP (1) JP6000259B2 (pt)
KR (1) KR20130136988A (pt)
CN (1) CN103221061A (pt)
AU (1) AU2011313505B2 (pt)
BR (1) BR112013008034A2 (pt)
CA (1) CA2812888A1 (pt)
DK (1) DK2624859T3 (pt)
ES (1) ES2625153T3 (pt)
HU (1) HUE033204T2 (pt)
MX (1) MX343784B (pt)
PL (1) PL2624859T3 (pt)
RU (1) RU2606155C2 (pt)
SG (2) SG10201508159SA (pt)
WO (1) WO2012045569A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6000259B2 (ja) 2010-10-06 2016-09-28 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 止血障害治療用第ｉｉ因子およびフィブリノーゲン
IL230150A0 (en) 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
AU2018217375B2 (en) * 2017-02-09 2024-04-18 Csl Behring Gmbh A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002105A1 (en) * 1980-01-28 1981-08-06 Baxter Travenol Lab Therapeutic compositions & methods for manufacture and use
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DE59712322D1 (de) * 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
KR20030088430A (ko) 2001-02-05 2003-11-19 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드 및 인자 ⅸ 폴리펩티드의 조합 사용
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
RU2298416C2 (ru) * 2001-07-20 2007-05-10 Ново Нордиск Хелт Кэр Аг Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора xi
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
EP1587424A4 (en) 2002-12-31 2012-01-25 Marinepolymer Tech Inc Bleeding Compounds and their uses
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ES2399277T3 (es) 2004-05-27 2013-03-27 Baxter International Inc. Procedimiento de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CN101501216B (zh) * 2006-03-06 2013-10-02 胡玛基因公司 制备重组人凝血酶的方法
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
US20090148502A1 (en) 2006-10-23 2009-06-11 Hemo Nanoscience, Llc Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
CA2682405A1 (en) 2007-03-30 2008-10-09 Thrombodyne, Inc. Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
SG174077A1 (en) 2007-04-13 2011-09-29 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
US20100086529A1 (en) 2008-10-08 2010-04-08 Mohammad Syed F Methods of making concentrated fibrinogen- and platelet-containing compositions
JP6000259B2 (ja) 2010-10-06 2016-09-28 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 止血障害治療用第ｉｉ因子およびフィブリノーゲン

Also Published As

Publication number Publication date
ES2625153T3 (es) 2017-07-18
WO2012045569A9 (en) 2016-01-07
SG10201508159SA (en) 2015-10-29
DK2624859T3 (en) 2017-06-06
JP6000259B2 (ja) 2016-09-28
SG188639A1 (en) 2013-05-31
KR20130136988A (ko) 2013-12-13
RU2606155C2 (ru) 2017-01-10
HUE033204T2 (en) 2017-11-28
PL2624859T3 (pl) 2017-09-29
MX2013003715A (es) 2013-09-26
US9433664B2 (en) 2016-09-06
CA2812888A1 (en) 2012-04-12
MX343784B (es) 2016-11-23
US20130280236A1 (en) 2013-10-24
RU2013120033A (ru) 2014-11-20
JP2013538863A (ja) 2013-10-17
AU2011313505A1 (en) 2013-04-11
EP2624859B1 (en) 2017-03-01
EP2624859A1 (en) 2013-08-14
WO2012045569A1 (en) 2012-04-12
AU2011313505B2 (en) 2015-09-17
CN103221061A (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
NZ630239A (en) Methods of treating melanoma
BR112013025047A2 (pt) composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
NZ602219A (en) Methods and compositions for treating degos’ disease
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
BRPI0901553A2 (pt) máscara facial
CO6781465A2 (es) Composición farmacéutica, métodos de tratamiento y usos de la misma
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112012012476A2 (pt) "composições nutritivas incluindo um componente de alta proteína e nucleotídeos exôgenos"
BR112013008034A2 (pt) método para normalizar hemeostase comprometida
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112014006587A2 (pt) modulação antisense da expressão de gcgr
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112013026976A2 (pt) alfa glucosidade ácida modificada com processamento acelerado
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
BR112012021670A2 (pt) dispositivo, sistemas e métodos de administração de agentes terapêuticos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.